• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    An evaluation of cetuximab dosing strategies using pharmacokinetics and cost analysis

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Ogungbenro, Kayode
    Patel, Alkesh
    Saunders, Mark P
    Clark, James
    Duncombe, Robert
    Affiliation
    Centre for Applied Pharmacokinetic Research, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
    Issue Date
    2019
    
    Metadata
    Show full item record
    Abstract
    OBJECTIVES: Cetuximab dosing is based on body surface area (BSA), an approach that is associated with significant wastage due to available vial sizes. NHS England recently introduced an alternative strategy for cetuximab dosing based on dose banding. The aim of this work was to investigate approaches to cetuximab dosing to improve its cost-effectiveness. METHODS: A simulation study using a population pharmacokinetic model was used to assess the performance of dosing strategies using exposure, probability of target attainment and cost. Two dosage regimens (500 and 400/250 mg/m2 ) were investigated; 5% and 10% dose banding, fixed and optimised dosing strategies were evaluated and compared to BSA strategy. KEY FINDINGS: The percentage of the total cost associated with wastage for the 400/250 mg/m2 regimen were 8.75%, 5.13%, 3.61%, 9.2% and 0% for BSA; 5 and 10% bands; fixed and optimal strategies, respectively. Similar results were obtained for 500 mg/m2 regimen. In comparison with BSA strategy, other strategies have comparable or improved performance. Optimised strategy showed consistent performance and ensures equal exposure and probability of target attainment. CONCLUSIONS: Cost-effectiveness of cetuximab treatment can be improved with alternative strategies by reducing wastage without compromising exposure.
    Citation
    Ogungbenro K, Patel A, Saunders M, Clark J, Duncombe R. An evaluation of cetuximab dosing strategies using pharmacokinetics and cost analysis. J Pharm Pharmacol. 2019.
    Journal
    The Journal of pharmacy and pharmacology
    URI
    http://hdl.handle.net/10541/621890
    DOI
    10.1111/jphp.13108
    PubMed ID
    31124587
    Additional Links
    https://dx.doi.org/10.1111/jphp.13108
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1111/jphp.13108
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents.
    • Authors: Chatelut E, White-Koning ML, Mathijssen RH, Puisset F, Baker SD, Sparreboom A
    • Issue date: 2012 Sep 25
    • A real-world data approach to determine the optimal dosing strategy for pembrolizumab.
    • Authors: Jang A, Nakashima L, Ng T, Fung M, Jiwani S, Schaff K, Suess J, Goncalves R, Jang D, Kuik K, Labelle S, Pow A
    • Issue date: 2021 Apr
    • Cetuximab Exhibits Sex Differences in Lymphatic Exposure after Intravenous Administration in Rats in the Absence of Differences in Plasma Exposure.
    • Authors: Kuilamu E, Subasic C, Cowin GJ, Simpson F, Minchin RF, Kaminskas LM
    • Issue date: 2020 Oct 19
    • Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis.
    • Authors: Ogungbenro K, Patel A, Duncombe R, Nuttall R, Clark J, Lorigan P
    • Issue date: 2018 Apr
    • The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
    • Authors: Huxley N, Crathorne L, Varley-Campbell J, Tikhonova I, Snowsill T, Briscoe S, Peters J, Bond M, Napier M, Hoyle M
    • Issue date: 2017 Jun
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.